CALIXAR’s technology aids clients to discover or generate innovative vaccines with larger efficiency and less antigen. We also support developing commercialized vaccines.
CALIXAR manufactures leading-quality and native antigens for vaccine development (animal, human fields). Our approach is particularly compatible with splitting vaccines and multi-subunit (recombinant) vaccines.
CALIXAR also identifies new markers for virulence and is able to produce them for developing new vaccines in particular for antibacterial vaccines.
Our technology enables Pharma, biotechs, and academics to generate vaccines with greater effectiveness and fewer antigens. We also promote the discovery and production of new antigens for generating new vaccines (in particular for unmet needs) or improving commercialized vaccines.
CALIXAR’s technology preserves the structural and functional integrities of the antigens enabling sound recognition of specific antibodies and generating strong immune responses.
Traditionally, vaccine discovery was performed with weak-quality antigens (low immunogenicity) and assay conflicts (antigen’s buffer conditions).
However, CALIXAR delivers high-quality native, pure, stable and functional membrane protein targets compatible with all vaccine discovery requests.
Our membrane proteins are ideal for vaccine discovery scientists such as pharma, biotechs, and academics involved in virology, vaccine and antibody development.
We utilize our patented technology and customizes every vaccine discovery project for our clients.
Virus splitting is a key step for vaccine preparation process that requires detergent use. However, it is challenging to obtain an efficient virus splitting while maintaining immunogenicity using classical detergents. CALIXAR has developed an innovative proprietary surfactant and detergent based approach consisting either on facilitating splitting of native viruses, fragmentation of bacteria, monitoring the solubilization and the stabilization of viral antigens without mutagenesis.
We previously reported the use of novel approaches to enable low dose split inactivated vaccine protection against influenza infection (Mandon E et al., Vaccine, 2020). Great results were also obtained for the discovery of new treatments against other challenging enveloped viruses such as Arbovirus and good progress on HIV as well (Jawhari A et al., World Vaccine Congress, Washington 2017).
Work plan used to generate and analyze fragmentation of purified egg-based NYMC X-179A (A(H1N1)) virus using triton-X100 or CALX-R compound. This includes virus production, virus fragmentation, dialysis/ultrafiltration/formaldehyde inactivation, in vitro hemagglutination (HA) and single radial immunodiffusion assays (SRID), and in vivo validation.
For more information on our approach four vaccines contact us.
The CALIXAR® platform uses patented technologies only available for clients under specific contracts (license, co-development, and service).
You can leverage CALIXAR’s proprietary technology as well as additional first-in-class membrane protein technology not obtainable anyplace else on the market.